Skip to main content

ADC Therapeutics SA 10-Q for FY2026 Q3

ADC Therapeutics SA (ADCT)

10-Q 2026-11-09 For: 2026-09-30
View Original
Added on November 09, 2026

About this 10-Q

ADC Therapeutics SA filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

ADC Therapeutics reported that Phase 3 LOTIS-5 showed significantly improved progression-free survival with ZYNLONTA plus rituximab versus R-GemOx in 420 patients; median PFS was 6.14 months versus 4.73 months. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$21.72M
up 32.2% from $16.43M a year earlier
Net loss
$25.3M
compared with a net loss of $40.97M a year earlier
Diluted EPS
-$0.16
compared with -$0.30 a year earlier